Avalo Therapeutics (AVTX) Change in Cash (2014 - 2026)
Avalo Therapeutics posted quarterly Change in Cash of $9.2 million for Q1 2026, up 197.42% year-on-year from $3.1 million in Q1 2025, and up 182.57% on a QoQ basis from -$11.2 million in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Change in Cash data on file, last reported at $9.2 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Cash rose 197.42% year-over-year to $9.2 million; the trailing twelve-month figure through Mar 2026 stood at -$99.9 million (down 769.44% YoY), and the FY2025 full-year result was -$118.6 million, down 193.27% from the prior year.
- Change in Cash for Q1 2026 stood at $9.2 million, up from -$11.2 million in the prior quarter.
- Across five years, Change in Cash topped out at $102.8 million in Q1 2024 and bottomed at -$82.7 million in Q2 2025.
- The 5-year median for Change in Cash is -$9.5 million (2025), against an average of -$1.7 million.
- The widest annual swing landed in 2022, when Change in Cash tumbled 1444.51%; it then surged 2784.25% in 2024.
- A 5-year view of Change in Cash shows it stood at -$3.9 million in 2022, then grew by 28.33% to -$2.8 million in 2023, then soared by 2004.7% to $52.7 million in 2024, then sank by 121.19% to -$11.2 million in 2025, then soared by 182.57% to $9.2 million in 2026.
- The last three Change in Cash figures came in at $9.2 million (Q1 2026), -$11.2 million (Q4 2025), and -$15.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 623.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 417.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -153.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 53.61 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 9.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.21 Mn |
| Dec 31, 2025 | -11.16 Mn |
| Sep 30, 2025 | -15.26 Mn |
| Jun 30, 2025 | -82.72 Mn |
| Mar 31, 2025 | -9.46 Mn |
| Dec 31, 2024 | 52.67 Mn |
| Sep 30, 2024 | -11.53 Mn |
| Jun 30, 2024 | -16.76 Mn |
| Mar 31, 2024 | 102.77 Mn |
| Dec 31, 2023 | -2.77 Mn |
| Sep 30, 2023 | 3.86 Mn |
| Jun 30, 2023 | -10.43 Mn |
| Mar 31, 2023 | 3.56 Mn |
| Dec 31, 2022 | -3.86 Mn |
| Sep 30, 2022 | 5.69 Mn |
| Jun 30, 2022 | -27.31 Mn |
| Mar 31, 2022 | -16.07 Mn |
| Dec 31, 2021 | -17.03 Mn |
| Sep 30, 2021 | 31.27 Mn |
| Jun 30, 2021 | 2.03 Mn |
| Mar 31, 2021 | 19.49 Mn |
| Dec 31, 2020 | -14.57 Mn |
| Sep 30, 2020 | -11.93 Mn |
| Jun 30, 2020 | 39.77 Mn |
| Mar 31, 2020 | 2.11 Mn |
| Dec 31, 2019 | -1.73 Mn |
| Sep 30, 2019 | -4.11 Mn |
| Jun 30, 2019 | -6.71 Mn |
| Mar 31, 2019 | 5.53 Mn |
| Dec 31, 2018 | 3.69 Mn |
| Sep 30, 2018 | 4.69 Mn |
| Jun 30, 2018 | -304,897.00 |
| Mar 31, 2018 | 63,742.00 |
| Dec 31, 2017 | -21.44 Mn |
| Sep 30, 2017 | 18.51 Mn |
| Jun 30, 2017 | 2.45 Mn |
| Mar 31, 2017 | -2.12 Mn |
| Dec 31, 2016 | -3.69 Mn |
| Sep 30, 2016 | -3.06 Mn |
| Jun 30, 2016 | -4.72 Mn |
| Mar 31, 2016 | -4.56 Mn |
| Dec 31, 2015 | 17.85 Mn |
| Sep 30, 2015 | -2.83 Mn |
| Jun 30, 2015 | -2.51 Mn |
| Mar 31, 2015 | -3.09 Mn |
| Dec 31, 2014 | -3.99 Mn |